N
Nan Lin
Researcher at Harvard University
Publications - 1220
Citations - 65601
Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.
Papers
More filters
Journal ArticleDOI
Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer
TL;DR: The two articles that accompany this editorial directly address several related questions: is there a preferred anti-HER2 therapy for use in the first-line setting?
Journal ArticleDOI
Biofilm development under different pipe materials and water quality conditions in raw water transportation system: Bacterial communities and nitrogen transformation
Nan Lin,Xing Li,Xiao-Yan Fan +2 more
TL;DR: In this article , the authors investigated the pollutants removal, bacterial community (abundant, rare and functional taxa) variations, and their correlations during biofilm development process under different pipe materials and raw water quality.
Journal ArticleDOI
Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM)
Rachel A. Freedman,Si-qun Ren,Nabihah Tayob,Rebecca Gelman,Karen Smith,Raechel Davis,Alyssa Pereslete,V. Attaya,Christine M Cotter,Wendy Y. Chen,Cesar A. Santa-Maria,Catherine Van Poznak,Beverly Moy,Adam Brufsky,Michelle E. Melisko,Ciara C. O’Sullivan,N I Ashai,Yasmeen Rauf,Julie R. Nangia,Dario Trapani,Jennifer Savoie,Robyn Burns,Antonio C. Wolff,Eric P. Winer,Mothaffar F. Rimawi,Ian E. Krop,Nan Lin +26 more
TL;DR: In this article , the authors reported results of neratinib plus T-DM1 in pts with HER2+ BCBM, with a volumetric central nervous system objective response rate (CNS ORR) of 49% in lapatinib-naïve patients.
Journal ArticleDOI
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.
Rachel A. Freedman,Ines Maria Vaz Duarte Luis,William T. Barry,Ian E. Krop,Nikhil Wagle,Alarice C. Lowe,Sarah R Galler,Jessica Sohl,Steven J. Isakoff,Nadine Tung,Eric P. Winer,Nan Lin +11 more
TL;DR: A single agent, eribulin is associated with prolonged overall survival compared to treatment of physician’s choice in pts with heavily pre-treated metastatic breast cancer (MB...
Journal ArticleDOI
Reply to H.L. McArthur et al
Ines Vaz-Luis,Nan Lin +1 more
TL;DR: These analyses were undertaken to better define the absolute risks of recurrence which could be used to estimate benefits of chemotherapy and trastuzumab and allow more informed decision-making on the part of patients and physicians.